Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
Rhea-AI Summary
Invivyd (Nasdaq: IVVD) has announced its participation in the upcoming Guggenheim Securities Healthcare Innovation Conference in Boston, MA. The company's management will engage in a fireside chat scheduled for Wednesday, November 13, 2024, at 2:30 PM ET, along with conducting one-on-one investor meetings during the conference, which runs from November 11-13, 2024.
A live webcast of the presentation will be accessible through the investor section of Invivyd's website and will remain available for approximately 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – IVVD
On the day this news was published, IVVD gained 12.62%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
WALTHAM, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that management will participate in a fireside chat and 1x1 investor meetings at the Guggenheim Securities Healthcare Innovation Conference taking place November 11-13, 2024.
Fireside Chat: Wednesday, November 13, 2024 at 2:30 PM ET
Location: Boston, MA
The live webcast link will be available in the investor section of the company's website at https://investors.invivyd.com and will be archived for approximately 30 days following the event.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
Contacts:
Media Relations
(781) 208-1747
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
FAQ
When is Invivyd (IVVD) presenting at the Guggenheim Securities Healthcare Conference 2024?
Where can I watch Invivyd's (IVVD) Guggenheim Securities Conference presentation?
What type of meetings will Invivyd (IVVD) conduct at the Guggenheim Healthcare Conference?
How long will Invivyd's (IVVD) Guggenheim Conference presentation be available online?
